Quadrant Capital Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Quadrant Capital Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-51	Closed	-$634	–	1305
2026 Q1	$634	Buy	+51	New	+$685	﹤0.01%	2621
2023 Q2	–	Sell	-328	Closed	-$456	–	2686
2023 Q1	$456	Sell	328 -2,144	-87%	-$4.27K	﹤0.01%	2615
2022 Q4	$4.92K	Buy	2,472 +1,726	+231%	+$3.87K	﹤0.01%	2200
2022 Q3	$2K	Buy	+746	New	+$2.09K	﹤0.01%	2326
2019 Q3	–	Sell	-119	Closed	–	–	2287
2019 Q2	$0	Hold	119	–	–	﹤0.01%	2310
2019 Q1	$1K	Sell	119 -24	-17%	-$317	﹤0.01%	2127
2018 Q4	$1K	Sell	143 -46	-24%	-$829	﹤0.01%	2012
2018 Q3	$3K	Hold	189	–	–	﹤0.01%	1686
2018 Q2	$2K	Buy	+189	New	+$3.32K	﹤0.01%	1829

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Quadrant Capital Group's AMRX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 51 shares — an estimated $634 sold.

Quadrant Capital Group first reported a position in AMRX in Q2 2018 and held it in 9 quarters. The position peaked at $4.92K in Q4 2022. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Quadrant Capital Group reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 51 Amneal Pharmaceuticals shares in Q2 2026, an estimated $634.
Quadrant Capital Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 9 quarters.
Quadrant Capital Group's Amneal Pharmaceuticals position peaked at $4.92K in Q4 2022.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.